Movatterモバイル変換

drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Plan optimal sample size allocation and go/no-go decision rules for phase II/III drug development programs with time-to-event, binary or normally distributed endpoints when assuming fixed treatment effects or a prior distribution for the treatment effect, using methods from Kirchner et al. (2016) <doi:10.1002/sim.6624> and Preussler (2020). Optimal is in the sense of maximal expected utility, where the utility is a function taking into account the expected cost and benefit of the program. It is possible to extend to more complex settings with bias correction (Preussler S et al. (2020) <doi:10.1186/s12874-020-01093-w>), multiple phase III trials (Preussler et al. (2019) <doi:10.1002/bimj.201700241>), multi-arm trials (Preussler et al. (2019) <doi:10.1080/19466315.2019.1702092>), and multiple endpoints (Kieser et al. (2018) <doi:10.1002/pst.1861>).

Version:	1.0.2
Depends:	R (≥ 3.5.0),doParallel, parallel,foreach,iterators
Imports:	mvtnorm,cubature,msm,MASS, stats,progressr
Suggests:	rmarkdown,knitr,testthat (≥ 3.0.0),covr,kableExtra,magrittr,devtools
Published:	2025-01-14
DOI:	10.32614/CRAN.package.drugdevelopR
Author:	Stella Erdmann [aut], Johannes Cepicka [aut], Marietta Kirchner [aut], Meinhard Kieser [aut], Lukas D. Sauer [aut, cre]
Maintainer:	Lukas D. Sauer <sauer at imbi.uni-heidelberg.de>
BugReports:	https://github.com/Sterniii3/drugdevelopR/issues
License:	MIT + fileLICENSE
URL:	https://github.com/Sterniii3/drugdevelopR,https://sterniii3.github.io/drugdevelopR/
NeedsCompilation:	no
Materials:	README,NEWS
CRAN checks:	drugdevelopR results

Documentation:

Downloads:

Linking:

Please use the canonical formhttps://CRAN.R-project.org/package=drugdevelopRto link to this page.